Overview

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

Status:
Completed

Trial end date:
2018-08-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

TG Therapeutics, Inc.

Collaborator:

SCRI Development Innovations, LLC

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Fluorouracil
Folic Acid
Gemcitabine
Leucovorin
Levoleucovorin
Oxaliplatin
Paclitaxel